The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | Genomic risk stratification and treatment consistency in myeloma
Francesco Maura, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the importance of consistent treatment approaches and risk stratification in multiple myeloma. Dr Maura highlights the role of daratumumab-based quadruplet regimens in newly diagnosed patients and emphasizes the need to accurately identify high-risk smoldering myeloma using the International Myeloma Working Group (IMWG) 2020 criteria, while avoiding unnecessary treatment in lower-risk patients. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
